Business
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
BRISBANE, Calif., January 07, 2026--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to eluci
About this update from Caredx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a5f0c5beb3b5dd62532bde76c404fcdb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rrmX4DXiHmmkcvQz9CMC4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a5f0c5beb3b5dd62532bde76c404fcdb","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zdgBu8fthsB1e7nyWE26HA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a5f0c5beb3b5dd62532bde76c404fcdb","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling","length":181,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., January 07, 2026--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.","length":690,"tagName":"p"},{"type":"text","content":"CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this initiative, which aims to generate high-resolution maps of the complex immune mechanisms underlying organ rejection associated with AMR and MVI. These data may help characterize disease origin and trajectory, as well as therapeutic response, laying the groundwork for future breakthroughs with potential to advance personalized transplant medicine.","length":439,"tagName":"p"},{"type":"text","content":""This collaboration marks a meaningful step in advancing precision transplant care," said John Hanna, President & CEO of CareDx. "...